Report Summary Catalogue Methodological

Definition and Scope:
Molecular diagnostics in point of care refer to the use of molecular biology techniques to analyze biological markers in a patient's sample at or near the site of patient care. This approach enables rapid and accurate diagnosis of various diseases, including infectious diseases, genetic disorders, and certain types of cancer. Molecular diagnostics in point of care can provide healthcare professionals with real-time information, allowing for timely decision-making regarding patient management and treatment strategies. By bringing advanced molecular testing capabilities closer to the patient, this technology has the potential to revolutionize healthcare delivery by improving diagnostic accuracy, reducing turnaround times, and enhancing patient outcomes.
The market for molecular diagnostics in point of care is experiencing significant growth driven by several key factors. One of the primary market drivers is the increasing demand for rapid and accurate diagnostic testing in various healthcare settings, including hospitals, clinics, and physician offices. The shift towards personalized medicine and precision healthcare is also fueling the adoption of molecular diagnostics in point of care, as these technologies enable tailored treatment strategies based on individual patient profiles. Additionally, advancements in technology, such as the development of miniaturized testing platforms and portable devices, are making molecular diagnostics more accessible and user-friendly for healthcare providers. Moreover, the growing prevalence of infectious diseases and the need for early detection and monitoring are further driving the market for molecular diagnostics in point of care.
In addition to these drivers, the market for molecular diagnostics in point of care is also influenced by factors such as increasing investments in research and development, expanding applications of molecular testing in different disease areas, and rising awareness about the benefits of early disease detection. As healthcare systems worldwide continue to prioritize value-based care and patient-centered approaches, the demand for rapid and accurate diagnostic solutions like molecular diagnostics in point of care is expected to rise. With ongoing technological innovations and collaborations between industry players and healthcare providers, the market for molecular diagnostics in point of care is poised for continued growth and evolution in the coming years.
The global Molecular Diagnostics in Point of Care market size was estimated at USD 633.15 million in 2024, exhibiting a CAGR of 5.00% during the forecast period.
This report offers a comprehensive analysis of the global Molecular Diagnostics in Point of Care market, examining all key dimensions. It provides both a macro-level overview and micro-level market details, including market size, trends, competitive landscape, niche segments, growth drivers, and key challenges.
Report Framework and Key Highlights: Market Dynamics: Identification of major market drivers, restraints, opportunities, and challenges.
Trend Analysis: Examination of ongoing and emerging trends impacting the market.
Competitive Landscape: Detailed profiles and market positioning of major players, including market share, operational status, product offerings, and strategic developments.
Strategic Analysis Tools: SWOT Analysis, Porter’s Five Forces Analysis, PEST Analysis, Value Chain Analysis
Market Segmentation: By type, application, region, and end-user industry.
Forecasting and Growth Projections: In-depth revenue forecasts and CAGR analysis through 2033.
This report equips readers with critical insights to navigate competitive dynamics and develop effective strategies. Whether assessing a new market entry or refining existing strategies, the report serves as a valuable tool for:
Industry players
Investors
Researchers
Consultants
Business strategists
And all stakeholders with an interest or investment in the Molecular Diagnostics in Point of Care market.
Global Molecular Diagnostics in Point of Care Market: Segmentation Analysis and Strategic Insights
This section of the report provides an in-depth segmentation analysis of the global Molecular Diagnostics in Point of Care market. The market is segmented based on region (country), manufacturer, product type, and application. Segmentation enables a more precise understanding of market dynamics and facilitates targeted strategies across product development, marketing, and sales.
By breaking the market into meaningful subsets, stakeholders can better tailor their offerings to the specific needs of each segment—enhancing competitiveness and improving return on investment.
Global Molecular Diagnostics in Point of Care Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Companies Profiled
Abbott
Accelerate Diagnostics
Ador Diagnostics
Beckman Coulter
Becton
Dickinson and Company
Binx Health
Biocartis
bioMérieux
Bio-Rad Laboratories
Bosch Healthcare Solutions
Curetis
Eurofins Scientific
Genetic Signatures
Grifols
Hibergene Diagnostics
Lumos Diagnostics
Roche
Siemens
Thermo Fisher Scientific
Market Segmentation by Type
Polymerase Chain Reaction
In Situ Hybridization
Gene Chips
Next Generation Sequencing
Market Segmentation by Application
Hospitals and Clinics
Independent Clinical Laboratories
Geographic Segmentation North America: United States, Canada, Mexico
Europe: Germany, France, Italy, U.K., Spain, Sweden, Denmark, Netherlands, Switzerland, Belgium, Russia.
Asia-Pacific: China, Japan, South Korea, India, Australia, Indonesia, Malaysia, Philippines, Singapore, Thailand
South America: Brazil, Argentina, Colombia.
Middle East and Africa (MEA): Saudi Arabia, United Arab Emirates, Egypt, Nigeria, South Africa, Rest of MEA
Report Framework and Chapter Summary Chapter 1: Report Scope and Market Definition
This chapter outlines the statistical boundaries and scope of the report. It defines the segmentation standards used throughout the study, including criteria for dividing the market by region, product type, application, and other relevant dimensions. It establishes the foundational definitions and classifications that guide the rest of the analysis.
Chapter 2: Executive Summary
This chapter presents a concise summary of the market’s current status and future outlook across different segments—by geography, product type, and application. It includes key metrics such as market size, growth trends, and development potential for each segment. The chapter offers a high-level overview of the Molecular Diagnostics in Point of Care Market, highlighting its evolution over the short, medium, and long term.
Chapter 3: Market Dynamics and Policy Environment
This chapter explores the latest developments in the market, identifying key growth drivers, restraints, challenges, and risks faced by industry participants. It also includes an analysis of the policy and regulatory landscape affecting the market, providing insight into how external factors may shape future performance.
Chapter 4: Competitive Landscape
This chapter provides a detailed assessment of the market's competitive environment. It covers market share, production capacity, output, pricing trends, and strategic developments such as mergers, acquisitions, and expansion plans of leading players. This analysis offers a comprehensive view of the positioning and performance of top competitors.
Chapters 5–10: Regional Market Analysis
These chapters offer in-depth, quantitative evaluations of market size and growth potential across major regions and countries. Each chapter assesses regional consumption patterns, market dynamics, development prospects, and available capacity. The analysis helps readers understand geographical differences and opportunities in global markets.
Chapter 11: Market Segmentation by Product Type
This chapter examines the market based on product type, analyzing the size, growth trends, and potential of each segment. It helps stakeholders identify underexplored or high-potential product categories—often referred to as “blue ocean” opportunities.
Chapter 12: Market Segmentation by Application
This chapter analyzes the market based on application fields, providing insights into the scale and future development of each application segment. It supports readers in identifying high-growth areas across downstream markets.
Chapter 13: Company Profiles
This chapter presents comprehensive profiles of leading companies operating in the market. For each company, it details sales revenue, volume, pricing, gross profit margin, market share, product offerings, and recent strategic developments. This section offers valuable insight into corporate performance and strategy.
Chapter 14: Industry Chain and Value Chain Analysis
This chapter explores the full industry chain, from upstream raw material suppliers to downstream application sectors. It includes a value chain analysis that highlights the interconnections and dependencies across various parts of the ecosystem.
Chapter 15: Key Findings and Conclusions
The final chapter summarizes the main takeaways from the report, presenting the core conclusions, strategic recommendations, and implications for stakeholders. It encapsulates the insights drawn from all previous chapters.

Table of Contents
1 Introduction to Research & Analysis Reports
1.1 Molecular Diagnostics in Point of Care Market Definition
1.2 Molecular Diagnostics in Point of Care Market Segments
1.2.1 Segment by Type
1.2.2 Segment by Application
2 Executive Summary
2.1 Global Molecular Diagnostics in Point of Care Market Size
2.2 Market Segmentation – by Type
2.3 Market Segmentation – by Application
2.4 Market Segmentation – by Geography
3 Key Market Trends, Opportunity, Drivers and Restraints
3.1 Key Takeway
3.2 Market Opportunities & Trends
3.3 Market Drivers
3.4 Market Restraints
3.5 Market Major Factor Assessment
4 Global Molecular Diagnostics in Point of Care Market Competitive Landscape
4.1 Global Molecular Diagnostics in Point of Care Sales by Manufacturers (2020-2025)
4.2 Global Molecular Diagnostics in Point of Care Revenue Market Share by Manufacturers (2020-2025)
4.3 Molecular Diagnostics in Point of Care Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.4 New Entrant and Capacity Expansion Plans
4.5 Mergers & Acquisitions
5 Global Molecular Diagnostics in Point of Care Market by Region
5.1 Global Molecular Diagnostics in Point of Care Market Size by Region
5.1.1 Global Molecular Diagnostics in Point of Care Market Size by Region
5.1.2 Global Molecular Diagnostics in Point of Care Market Size Market Share by Region
5.2 Global Molecular Diagnostics in Point of Care Sales by Region
5.2.1 Global Molecular Diagnostics in Point of Care Sales by Region
5.2.2 Global Molecular Diagnostics in Point of Care Sales Market Share by Region
6 North America Market Overview
6.1 North America Molecular Diagnostics in Point of Care Market Size by Country
6.1.1 USA Market Overview
6.1.2 Canada Market Overview
6.1.3 Mexico Market Overview
6.2 North America Molecular Diagnostics in Point of Care Market Size by Type
6.3 North America Molecular Diagnostics in Point of Care Market Size by Application
6.4 Top Players in North America Molecular Diagnostics in Point of Care Market
7 Europe Market Overview
7.1 Europe Molecular Diagnostics in Point of Care Market Size by Country
7.1.1 Germany Market Overview
7.1.2 France Market Overview
7.1.3 U.K. Market Overview
7.1.4 Italy Market Overview
7.1.5 Spain Market Overview
7.1.6 Sweden Market Overview
7.1.7 Denmark Market Overview
7.1.8 Netherlands Market Overview
7.1.9 Switzerland Market Overview
7.1.10 Belgium Market Overview
7.1.11 Russia Market Overview
7.2 Europe Molecular Diagnostics in Point of Care Market Size by Type
7.3 Europe Molecular Diagnostics in Point of Care Market Size by Application
7.4 Top Players in Europe Molecular Diagnostics in Point of Care Market
8 Asia-Pacific Market Overview
8.1 Asia-Pacific Molecular Diagnostics in Point of Care Market Size by Country
8.1.1 China Market Overview
8.1.2 Japan Market Overview
8.1.3 South Korea Market Overview
8.1.4 India Market Overview
8.1.5 Australia Market Overview
8.1.6 Indonesia Market Overview
8.1.7 Malaysia Market Overview
8.1.8 Philippines Market Overview
8.1.9 Singapore Market Overview
8.1.10 Thailand Market Overview
8.1.11 Rest of APAC Market Overview
8.2 Asia-Pacific Molecular Diagnostics in Point of Care Market Size by Type
8.3 Asia-Pacific Molecular Diagnostics in Point of Care Market Size by Application
8.4 Top Players in Asia-Pacific Molecular Diagnostics in Point of Care Market
9 South America Market Overview
9.1 South America Molecular Diagnostics in Point of Care Market Size by Country
9.1.1 Brazil Market Overview
9.1.2 Argentina Market Overview
9.1.3 Columbia Market Overview
9.2 South America Molecular Diagnostics in Point of Care Market Size by Type
9.3 South America Molecular Diagnostics in Point of Care Market Size by Application
9.4 Top Players in South America Molecular Diagnostics in Point of Care Market
10 Middle East and Africa Market Overview
10.1 Middle East and Africa Molecular Diagnostics in Point of Care Market Size by Country
10.1.1 Saudi Arabia Market Overview
10.1.2 UAE Market Overview
10.1.3 Egypt Market Overview
10.1.4 Nigeria Market Overview
10.1.5 South Africa Market Overview
10.2 Middle East and Africa Molecular Diagnostics in Point of Care Market Size by Type
10.3 Middle East and Africa Molecular Diagnostics in Point of Care Market Size by Application
10.4 Top Players in Middle East and Africa Molecular Diagnostics in Point of Care Market
11 Molecular Diagnostics in Point of Care Market Segmentation by Type
11.1 Evaluation Matrix of Segment Market Development Potential (Type)
11.2 Global Molecular Diagnostics in Point of Care Sales Market Share by Type (2020-2033)
11.3 Global Molecular Diagnostics in Point of Care Market Size Market Share by Type (2020-2033)
11.4 Global Molecular Diagnostics in Point of Care Price by Type (2020-2033)
12 Molecular Diagnostics in Point of Care Market Segmentation by Application
12.1 Evaluation Matrix of Segment Market Development Potential (Application)
12.2 Global Molecular Diagnostics in Point of Care Market Sales by Application (2020-2033)
12.3 Global Molecular Diagnostics in Point of Care Market Size (M USD) by Application (2020-2033)
12.4 Global Molecular Diagnostics in Point of Care Sales Growth Rate by Application (2020-2033)
13 Company Profiles
13.1 Abbott
13.1.1 Abbott Company Overview
13.1.2 Abbott Business Overview
13.1.3 Abbott Molecular Diagnostics in Point of Care Major Product Offerings
13.1.4 Abbott Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.1.5 Key News
13.2 Accelerate Diagnostics
13.2.1 Accelerate Diagnostics Company Overview
13.2.2 Accelerate Diagnostics Business Overview
13.2.3 Accelerate Diagnostics Molecular Diagnostics in Point of Care Major Product Offerings
13.2.4 Accelerate Diagnostics Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.2.5 Key News
13.3 Ador Diagnostics
13.3.1 Ador Diagnostics Company Overview
13.3.2 Ador Diagnostics Business Overview
13.3.3 Ador Diagnostics Molecular Diagnostics in Point of Care Major Product Offerings
13.3.4 Ador Diagnostics Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.3.5 Key News
13.4 Beckman Coulter
13.4.1 Beckman Coulter Company Overview
13.4.2 Beckman Coulter Business Overview
13.4.3 Beckman Coulter Molecular Diagnostics in Point of Care Major Product Offerings
13.4.4 Beckman Coulter Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.4.5 Key News
13.5 Becton
13.5.1 Becton Company Overview
13.5.2 Becton Business Overview
13.5.3 Becton Molecular Diagnostics in Point of Care Major Product Offerings
13.5.4 Becton Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.5.5 Key News
13.6 Dickinson and Company
13.6.1 Dickinson and Company Company Overview
13.6.2 Dickinson and Company Business Overview
13.6.3 Dickinson and Company Molecular Diagnostics in Point of Care Major Product Offerings
13.6.4 Dickinson and Company Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.6.5 Key News
13.7 Binx Health
13.7.1 Binx Health Company Overview
13.7.2 Binx Health Business Overview
13.7.3 Binx Health Molecular Diagnostics in Point of Care Major Product Offerings
13.7.4 Binx Health Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.7.5 Key News
13.8 Biocartis
13.8.1 Biocartis Company Overview
13.8.2 Biocartis Business Overview
13.8.3 Biocartis Molecular Diagnostics in Point of Care Major Product Offerings
13.8.4 Biocartis Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.8.5 Key News
13.9 bioMérieux
13.9.1 bioMérieux Company Overview
13.9.2 bioMérieux Business Overview
13.9.3 bioMérieux Molecular Diagnostics in Point of Care Major Product Offerings
13.9.4 bioMérieux Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.9.5 Key News
13.10 Bio-Rad Laboratories
13.10.1 Bio-Rad Laboratories Company Overview
13.10.2 Bio-Rad Laboratories Business Overview
13.10.3 Bio-Rad Laboratories Molecular Diagnostics in Point of Care Major Product Offerings
13.10.4 Bio-Rad Laboratories Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.10.5 Key News
13.11 Bosch Healthcare Solutions
13.11.1 Bosch Healthcare Solutions Company Overview
13.11.2 Bosch Healthcare Solutions Business Overview
13.11.3 Bosch Healthcare Solutions Molecular Diagnostics in Point of Care Major Product Offerings
13.11.4 Bosch Healthcare Solutions Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.11.5 Key News
13.12 Curetis
13.12.1 Curetis Company Overview
13.12.2 Curetis Business Overview
13.12.3 Curetis Molecular Diagnostics in Point of Care Major Product Offerings
13.12.4 Curetis Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.12.5 Key News
13.13 Eurofins Scientific
13.13.1 Eurofins Scientific Company Overview
13.13.2 Eurofins Scientific Business Overview
13.13.3 Eurofins Scientific Molecular Diagnostics in Point of Care Major Product Offerings
13.13.4 Eurofins Scientific Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.13.5 Key News
13.14 Genetic Signatures
13.14.1 Genetic Signatures Company Overview
13.14.2 Genetic Signatures Business Overview
13.14.3 Genetic Signatures Molecular Diagnostics in Point of Care Major Product Offerings
13.14.4 Genetic Signatures Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.14.5 Key News
13.15 Grifols
13.15.1 Grifols Company Overview
13.15.2 Grifols Business Overview
13.15.3 Grifols Molecular Diagnostics in Point of Care Major Product Offerings
13.15.4 Grifols Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.15.5 Key News
13.16 Hibergene Diagnostics
13.16.1 Hibergene Diagnostics Company Overview
13.16.2 Hibergene Diagnostics Business Overview
13.16.3 Hibergene Diagnostics Molecular Diagnostics in Point of Care Major Product Offerings
13.16.4 Hibergene Diagnostics Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.16.5 Key News
13.17 Lumos Diagnostics
13.17.1 Lumos Diagnostics Company Overview
13.17.2 Lumos Diagnostics Business Overview
13.17.3 Lumos Diagnostics Molecular Diagnostics in Point of Care Major Product Offerings
13.17.4 Lumos Diagnostics Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.17.5 Key News
13.18 Roche
13.18.1 Roche Company Overview
13.18.2 Roche Business Overview
13.18.3 Roche Molecular Diagnostics in Point of Care Major Product Offerings
13.18.4 Roche Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.18.5 Key News
13.19 Siemens
13.19.1 Siemens Company Overview
13.19.2 Siemens Business Overview
13.19.3 Siemens Molecular Diagnostics in Point of Care Major Product Offerings
13.19.4 Siemens Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.19.5 Key News
13.20 Thermo Fisher Scientific
13.20.1 Thermo Fisher Scientific Company Overview
13.20.2 Thermo Fisher Scientific Business Overview
13.20.3 Thermo Fisher Scientific Molecular Diagnostics in Point of Care Major Product Offerings
13.20.4 Thermo Fisher Scientific Molecular Diagnostics in Point of Care Sales and Revenue fromMolecular Diagnostics in Point of Care (2020-2025)
13.20.5 Key News
14 Key Market Trends, Opportunity, Drivers and Restraints
14.1 Key Takeway
14.2 Market Opportunities & Trends
14.3 Market Drivers
14.4 Market Restraints
14.5 Market Major Factor Assessment
14.6 Porter's Five Forces Analysis of Molecular Diagnostics in Point of Care Market
14.7 PEST Analysis of Molecular Diagnostics in Point of Care Market
15 Analysis of the Molecular Diagnostics in Point of Care Industry Chain
15.1 Overview of the Industry Chain
15.2 Upstream Segment Analysis
15.3 Midstream Segment Analysis
15.3.1 Manufacturing, Processing or Conversion Process Analysis
15.3.2 Key Technology Analysis
15.4 Downstream Segment Analysis
15.4.1 Downstream Customer List and Contact Details
15.4.2 Customer Concerns or Preference Analysis
16 Conclusion
17 Appendix
17.1 Methodology
17.2 Research Process and Data Source
17.3 Disclaimer
17.4 Note
17.5 Examples of Clients
17.6 Disclaimer

Research Methodology
The research methodology employed in this study follows a structured, four-stage process designed to ensure the accuracy, consistency, and relevance of all data and insights presented. The process begins with Information Procurement, wherein data is collected from a wide range of primary and secondary sources. This is followed by Information Analysis, during which the collected data is systematically mapped, discrepancies across sources are examined, and consistency is established through cross-validation.

Subsequently, the Market Formulation phase involves placing verified data points into an appropriate market context to generate meaningful conclusions. This step integrates analyst interpretation and expert heuristics to refine findings and ensure applicability. Finally, all conclusions undergo a rigorous Validation and Publishing process, where each data point is re-evaluated before inclusion in the final deliverable. The methodology emphasizes bidirectional flow and reversibility between key stages to maintain flexibility and reinforce the integrity of the analysis.

Research Process
The market research process follows a structured and iterative methodology designed to ensure accuracy, depth, and reliability. It begins with scope definition and research design, where the research objectives are clearly outlined based on client requirements, emerging market trends, and initial exploratory insights. This phase provides strategic direction for all subsequent stages of the research.
Data collection is then conducted through both secondary and primary research. Secondary research involves analyzing publicly available and paid sources such as company filings, industry journals, and government databases to build foundational knowledge. This is followed by primary research, which includes direct interviews and surveys with key industry stakeholders—such as manufacturers, distributors, and end users—to gather firsthand insights and address data gaps identified earlier. Techniques included CATI (Computer-Assisted Telephonic Interviewing), CAWI (Computer-Assisted Web Interviewing), CAVI (Computer-Assisted Video Interviewing via platforms like Zoom and WebEx), and CASI (Computer-Assisted Self Interviewing via email or LinkedIn).